Jeffrey Ubben
ValueAct Holdings
Jeffrey Ubben Baker Hughes Co stake
total: 107
ValueAct Holdings BKR trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2017 Q3
- Held for:
- 1 quarter
- Latest activity:
- 2017 Q4
According to 2026 Q2 report, Jeffrey Ubben doesn't hold any Baker Hughes Co (BKR) shares. To date, the estimated cost basis is nearly $36.62 for "buy" trades and estimated average "sell" price is $36.62. ValueAct Holdings first purchased BKR in 2017 Q3, initially acquiring about 31.41M shares. Since the initial investment in Baker Hughes Co (BKR), ValueAct Holdings has made 1 more transaction.
When did Jeffrey Ubben sell Baker Hughes Co (BKR)?
Jeffrey Ubben sold off the entire Baker Hughes Co (BKR) position in 2017 Q4.
When did Jeffrey Ubben buy Baker Hughes Co (BKR)?
Jeffrey Ubben first invested in Baker Hughes Co (BKR) in 2017 Q3 at the reported quarter-end price of $36.62 per share.
What's the cost basis of ValueAct Holdings's BKR stake?
The estimated cost basis for Baker Hughes Co (BKR) stake is around $36.62 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $36.62
- Weighted AVG sell price:
- $36.62
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.